Clinical Trial Update: Secukinumab Dosage Optimisation in Partial Responders With Moderate to Severe Plaque-type Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 trial updating Secukinumab dosage optimization in partial responders with moderate to severe plaque psoriasis has completed; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque-type Psoriasis

Drugs mentioned

• Secukinumab (secukinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Moderate to Severe Plaque-type Psoriasis | Phase 3 | Status: COMPLETED | Results posted: 2019-07-05